000180368 001__ 180368
000180368 005__ 20240229145616.0
000180368 0247_ $$2doi$$a10.1186/s40364-022-00389-x
000180368 0247_ $$2pmid$$apmid:35715818
000180368 0247_ $$2altmetric$$aaltmetric:130374665
000180368 037__ $$aDKFZ-2022-01282
000180368 041__ $$aEnglish
000180368 082__ $$a610
000180368 1001_ $$aCatanzaro, Giuseppina$$b0
000180368 245__ $$aMiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.
000180368 260__ $$aLondon$$bBiomed Central$$c2022
000180368 3367_ $$2DRIVER$$aarticle
000180368 3367_ $$2DataCite$$aOutput Types/Journal article
000180368 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655727742_1692
000180368 3367_ $$2BibTeX$$aARTICLE
000180368 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180368 3367_ $$00$$2EndNote$$aJournal Article
000180368 520__ $$aPediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool.We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres.These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways.Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.
000180368 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000180368 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180368 650_7 $$2Other$$aPediatric low-grade gliomas
000180368 650_7 $$2Other$$aPersonalized medicine
000180368 650_7 $$2Other$$aPrognostic biomarker
000180368 650_7 $$2Other$$aRisk stratification
000180368 650_7 $$2Other$$aTumour progression
000180368 650_7 $$2Other$$amiR-1248
000180368 7001_ $$aBesharat, Zein Mersini$$b1
000180368 7001_ $$aCarai, Andrea$$b2
000180368 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b3$$udkfz
000180368 7001_ $$aSplendiani, Elena$$b4
000180368 7001_ $$aColin, Carole$$b5
000180368 7001_ $$aPo, Agnese$$b6
000180368 7001_ $$aChiacchiarini, Martina$$b7
000180368 7001_ $$aCitarella, Anna$$b8
000180368 7001_ $$aGianno, Francesca$$b9
000180368 7001_ $$aCacchione, Antonella$$b10
000180368 7001_ $$aMiele, Evelina$$b11
000180368 7001_ $$aDiomedi Camassei, Francesca$$b12
000180368 7001_ $$aGessi, Marco$$b13
000180368 7001_ $$aMassimi, Luca$$b14
000180368 7001_ $$aLocatelli, Franco$$b15
000180368 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b16$$udkfz
000180368 7001_ $$aFigarella-Branger, Dominique$$b17
000180368 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b18$$udkfz
000180368 7001_ $$aMastronuzzi, Angela$$b19
000180368 7001_ $$aGiangaspero, Felice$$b20
000180368 7001_ $$aFerretti, Elisabetta$$b21
000180368 773__ $$0PERI:(DE-600)2699926-2$$a10.1186/s40364-022-00389-x$$gVol. 10, no. 1, p. 44$$n1$$p44$$tBiomarker Research$$v10$$x2050-7771$$y2022
000180368 909CO $$ooai:inrepo02.dkfz.de:180368$$pVDB
000180368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000180368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000180368 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000180368 9141_ $$y2022
000180368 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-06-15
000180368 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-06-15
000180368 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-06-15
000180368 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-06-15
000180368 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-06-15
000180368 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMARK RES : 2021$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:19:51Z
000180368 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:19:51Z
000180368 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-14T16:19:51Z
000180368 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000180368 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBIOMARK RES : 2021$$d2022-11-19
000180368 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000180368 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180368 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x2
000180368 980__ $$ajournal
000180368 980__ $$aVDB
000180368 980__ $$aI:(DE-He78)B062-20160331
000180368 980__ $$aI:(DE-He78)HD01-20160331
000180368 980__ $$aI:(DE-He78)B360-20160331
000180368 980__ $$aUNRESTRICTED